SynCore Biotechnology Co., Ltd.


Chairman: Dr. Tim Lee
Date of Establishment: 2008/06
Tel: 886-2-2760-3688
Fax: 886-2-2763-9287
Address: 4F., No.69, Dongxing Rd., Xinyi Dist., Taipei City 110, Taiwan
Website: http://www.syncorebio.com/ Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


 

Company Brief Introduction:

SynCore Biotech Co., established in 2008 and was public listed in 2014, creating value of new drug by R&D management and integration of technology resources. 

SynCore forms a completely new drug development pipeline with five products: 

SB01 & SB02 (Anti-cancer NCE) which were in-licensed from NHRI; SB03 (Veregen®, an ointment treatment for external genital warts) was cooperated with Medigene (Germany listed company); SB04 (a conventional drug in new use of treating dry AMD) was in-licensed from MacuCLEAR, US; and SB05 (EndoTAG-1, treatment for triple negative breast cancer) also was in-licensed from Medigene.

Company Business Advantages: 

(1) Clear positioning and marketing strategies: Primarily for aging caused problems, such as cancer and eye related diseases. All the products form a completely new drug development pipeline to lower the risk of focusing on a single product development. (2) Specialized R&D team: with technology platform created and high-quality clinical trials management capabilities. (3) Integrating the most advanced academic resources and forming strategic alliances with international companies, as well as with intellectual property and investment management to shorten drug development time, and to expand business to the global market.

Development and The Vision: 

SynCore pipeline includes: (1) SB02 an anti-cancer NCE through oral route, formulation for clinical trial is under development. (2) SB01: an injectable anti-cancer NCE, phase I clinical trial has been conducting. (3) SB04: phase II/III clinical trial was approved by FDA and TFDA and has been conducting. (4) The SB05 (EndoTAG -1) CTA for phase III clinical trial was approved by FAMHP in Feb. 2014. (5) The NDA of Veregen® was approved by TFDA and launched in OCT. 2013. 

The pipeline covers the stages from preclinical to marketing of NUDrug® development of high but unmet medical needs. We are convinced the continuous R&D progress and abundant international collaboration will solid SynCore’s value to be seen.

New Drug in Development: